BioMarin Pharma (BMRN) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.26 -2.04%
Revenue Growth %: +31.4%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.07, $0.18 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $501.7 million versus the consensus estimate of $448.79 million.
GUIDANCE:
BioMarin Pharma sees FY 2021 revenue of $1.75-1.85 billion, versus the consensus of $1.82 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Amer Sports gains as Jefferies initiates at Buy citing Salomon, Arc’teryx momentum
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
